Healthcare provider profile · identity verified

Samuel Altidor, ARNP

Nurse Practitioner · HIGH POINT, NC · NPI 1912577008

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	359	141
Amlodipine Besylate	Amlodipine Besylate	294	114
Albuterol Sulfate Hfa	Albuterol Sulfate	257	89
Metformin Hcl	Metformin Hcl	242	84
Gabapentin	Gabapentin	206	74
Losartan Potassium	Losartan Potassium	157	67
Lisinopril	Lisinopril	153	64
Metoprolol Succinate	Metoprolol Succinate	148	58
Alprazolam	Alprazolam	129	36
Tramadol Hcl	Tramadol Hcl	127	59
Pantoprazole Sodium	Pantoprazole Sodium	122	54
Hydrochlorothiazide	Hydrochlorothiazide	113	46
Rosuvastatin Calcium	Rosuvastatin Calcium	100	47
Omeprazole	Omeprazole	98	43
Eliquis	Apixaban	94	26
Levothyroxine Sodium	Levothyroxine Sodium	90	40
Trazodone Hcl	Trazodone Hcl	89	29
Potassium Chloride	Potassium Chloride	88	34
Tizanidine Hcl	Tizanidine Hcl	83	37
Furosemide	Furosemide	82	40
Prednisone	Prednisone	82	60
Sertraline Hcl	Sertraline Hcl	82	21
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	79	29
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	78	28
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	76	25
Carvedilol	Carvedilol	73	25
Tamsulosin Hcl	Tamsulosin Hcl	66	29
Oxycodone Hcl	Oxycodone Hcl	65	21
Meloxicam	Meloxicam	62	21
Metoprolol Tartrate	Metoprolol Tartrate	62	25
Fluticasone Propionate	Fluticasone Propionate	58	27
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	58	16
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	57	22
Mirtazapine	Mirtazapine	54	20
Mounjaro	Tirzepatide	54	16
Pravastatin Sodium	Pravastatin Sodium	52	21
Clopidogrel	Clopidogrel Bisulfate	50	18
Duloxetine Hcl	Duloxetine Hcl	50	18
Hydralazine Hcl	Hydralazine Hcl	50	18
Spironolactone	Spironolactone	48	19
Ozempic	Semaglutide	47	18
Trulicity	Dulaglutide	47	16
Escitalopram Oxalate	Escitalopram Oxalate	44	20
Naproxen	Naproxen	41	18
Glipizide	Glipizide	40	16
Triamcinolone Acetonide	Triamcinolone Acetonide	40	24
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	39	20
Breo Ellipta	Fluticasone/Vilanterol	36	13
Nitroglycerin	Nitroglycerin	36	15
Pregabalin	Pregabalin	36	14
Simvastatin	Simvastatin	35	12
Lorazepam	Lorazepam	34	11
Buspirone Hcl	Buspirone Hcl	33	11
Jardiance	Empagliflozin	32	suppressed
Ondansetron Odt	Ondansetron	31	19
Montelukast Sodium	Montelukast Sodium	30	suppressed
Azithromycin	Azithromycin	29	29
Allopurinol	Allopurinol	28	15
Chlorthalidone	Chlorthalidone	28	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	28	12
Ezetimibe	Ezetimibe	27	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	27	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	25	22
Isosorbide Mononitrate Er	Isosorbide Mononitrate	25	suppressed
Januvia	Sitagliptin Phosphate	25	suppressed
Metformin Hcl Er	Metformin Hcl	25	12
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	25	suppressed
Famotidine	Famotidine	24	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	24	23
Tresiba Flextouch U-100	Insulin Degludec	24	suppressed
Amoxicillin	Amoxicillin	23	21
Celecoxib	Celecoxib	23	suppressed
Farxiga	Dapagliflozin Propanediol	23	suppressed
Humalog	Insulin Lispro	23	suppressed
Hydrocortisone	Hydrocortisone	22	suppressed
Omnipod Dash Pods (Gen 4)	Insulin Pump Cart,cont Inf,bt	22	suppressed
Meclizine Hcl	Meclizine Hcl	21	12
Quetiapine Fumarate	Quetiapine Fumarate	21	suppressed
Ventolin Hfa	Albuterol Sulfate	21	suppressed
Clonidine Hcl	Clonidine Hcl	20	suppressed
Temazepam	Temazepam	20	suppressed
Citalopram Hbr	Citalopram Hydrobromide	19	suppressed
Clonazepam	Clonazepam	19	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	18	suppressed
Divalproex Sodium	Divalproex Sodium	18	suppressed
Donepezil Hcl	Donepezil Hcl	18	suppressed
Fluconazole	Fluconazole	18	15
Nitrofurantoin	Nitrofurantoin Macrocrystal	18	suppressed
Symbicort	Budesonide/Formoterol Fumarate	18	11
Zolpidem Tartrate	Zolpidem Tartrate	18	suppressed
Alendronate Sodium	Alendronate Sodium	17	suppressed
Baclofen	Baclofen	17	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	17	suppressed
Bupropion Hcl Sr	Bupropion Hcl	17	suppressed
Diclofenac Sodium	Diclofenac Sodium	17	suppressed
Topiramate	Topiramate	17	11
Bupropion Xl	Bupropion Hcl	16	suppressed
Sucralfate	Sucralfate	16	suppressed
Memantine Hcl	Memantine Hcl	15	suppressed
Atenolol	Atenolol	14	suppressed
Diazepam	Diazepam	14	suppressed
Torsemide	Torsemide	14	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Linzess	Linaclotide	13	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	13	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	13	suppressed
Promethazine Hcl	Promethazine Hcl	13	suppressed
Sulfasalazine	Sulfasalazine	13	suppressed
Valsartan	Valsartan	13	suppressed
Cephalexin	Cephalexin	12	suppressed
Fenofibrate	Fenofibrate	12	suppressed
Ondansetron Hcl	Ondansetron Hcl	12	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	12	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	12	suppressed
Digoxin	Digoxin	11	suppressed
Dilt-Xr	Diltiazem Hcl	11	suppressed
Methocarbamol	Methocarbamol	11	suppressed
Novolog	Insulin Aspart	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error